Last: | $0.425 |
---|---|
Change Percent: | 0.0% |
Open: | $0.4 |
Close: | $0.425 |
High: | $0.425 |
Low: | $0.3818 |
Volume: | 2,763,987 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.425 | $0.4 | $0.425 | $0.425 | $0.3818 | 2,763,987 | 07-04-2024 |
$0.425 | $0.4 | $0.425 | $0.425 | $0.3818 | 2,761,400 | 07-03-2024 |
$0.3918 | $0.375 | $0.3918 | $0.3918 | $0.3653 | 3,962,682 | 07-02-2024 |
$0.3762 | $0.4 | $0.3762 | $0.408 | $0.375 | 7,033,578 | 07-01-2024 |
$0.3912 | $0.4264 | $0.3912 | $0.4392 | $0.39 | 38,544,121 | 06-28-2024 |
$0.4233 | $0.4151 | $0.4233 | $0.434 | $0.4 | 5,196,549 | 06-27-2024 |
$0.402 | $0.4419 | $0.402 | $0.46 | $0.4006 | 3,110,689 | 06-26-2024 |
$0.442 | $0.42 | $0.442 | $0.442 | $0.42 | 3,077,571 | 06-25-2024 |
$0.4399 | $0.424 | $0.4399 | $0.45 | $0.4212 | 3,145,106 | 06-24-2024 |
$0.4235 | $0.4154 | $0.4235 | $0.4269 | $0.415 | 3,142,033 | 06-21-2024 |
$0.4177 | $0.4084 | $0.4177 | $0.425 | $0.4051 | 2,051,244 | 06-20-2024 |
$0.4089 | $0.395 | $0.4089 | $0.4249 | $0.395 | 2,521,495 | 06-19-2024 |
$0.4089 | $0.395 | $0.4089 | $0.4249 | $0.395 | 2,521,495 | 06-18-2024 |
$0.4 | $0.4 | $0.4 | $0.4085 | $0.39 | 3,067,234 | 06-17-2024 |
$0.3964 | $0.41 | $0.3964 | $0.41 | $0.39 | 3,111,170 | 06-14-2024 |
$0.412 | $0.4058 | $0.412 | $0.4245 | $0.402 | 4,203,527 | 06-13-2024 |
$0.4121 | $0.4029 | $0.4121 | $0.4259 | $0.4 | 3,449,832 | 06-12-2024 |
$0.4136 | $0.4 | $0.4136 | $0.4187 | $0.391 | 2,558,391 | 06-11-2024 |
$0.4029 | $0.391 | $0.4029 | $0.414 | $0.377 | 5,067,787 | 06-10-2024 |
$0.4041 | $0.3888 | $0.4041 | $0.419099 | $0.3852 | 4,350,060 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Hea...
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at h...
2024-06-04 12:48:12 ET Genetic database builder 23andMe (NASDAQ: ME) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal ...